Clinical Trials · NCT07614412
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Ministry of Health, Saudi Arabia
- Enrollment
- 240
- Start date
- Jan 2027
- Locations
- 1 site, Saudi Arabia
- Primary endpoint
- Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT)